CL2018001134A1 - Composiciones y métodos para inhibir la actividad arginasa - Google Patents
Composiciones y métodos para inhibir la actividad arginasaInfo
- Publication number
- CL2018001134A1 CL2018001134A1 CL2018001134A CL2018001134A CL2018001134A1 CL 2018001134 A1 CL2018001134 A1 CL 2018001134A1 CL 2018001134 A CL2018001134 A CL 2018001134A CL 2018001134 A CL2018001134 A CL 2018001134A CL 2018001134 A1 CL2018001134 A1 CL 2018001134A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- compositions
- arginase activity
- inhibit arginase
- inhibit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562248632P | 2015-10-30 | 2015-10-30 | |
| US201662281964P | 2016-01-22 | 2016-01-22 | |
| US201662323034P | 2016-04-15 | 2016-04-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018001134A1 true CL2018001134A1 (es) | 2018-10-26 |
Family
ID=58631120
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018001134A CL2018001134A1 (es) | 2015-10-30 | 2018-04-27 | Composiciones y métodos para inhibir la actividad arginasa |
| CL2019000820A CL2019000820A1 (es) | 2015-10-30 | 2019-03-28 | Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134) |
| CL2019000821A CL2019000821A1 (es) | 2015-10-30 | 2019-03-28 | Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134) |
| CL2019000819A CL2019000819A1 (es) | 2015-10-30 | 2019-03-28 | Compuestos y composiciones para inhibir la actividad arginasa. (divisional solicitud 201801134) |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019000820A CL2019000820A1 (es) | 2015-10-30 | 2019-03-28 | Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134) |
| CL2019000821A CL2019000821A1 (es) | 2015-10-30 | 2019-03-28 | Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134) |
| CL2019000819A CL2019000819A1 (es) | 2015-10-30 | 2019-03-28 | Compuestos y composiciones para inhibir la actividad arginasa. (divisional solicitud 201801134) |
Country Status (36)
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX348422B (es) | 2010-04-22 | 2017-06-12 | Mars Inc | Inhibidores de arginasa y sus aplicaciones terapeuticas. |
| JP5909239B2 (ja) | 2010-10-26 | 2016-04-26 | マーズ インコーポレイテッド | アルギナーゼ阻害剤としてのボロネート |
| CA3003271A1 (en) | 2015-10-30 | 2017-05-04 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| JP2020502259A (ja) * | 2016-11-08 | 2020-01-23 | カリセラ バイオサイエンシズ，インコーポレイテッド | アルギナーゼ阻害剤併用療法 |
| RS61996B1 (sr) * | 2016-12-22 | 2021-07-30 | Calithera Biosciences Inc | Kompozicije i postupci za inhibiranje aktivnosti arginaze |
| CR20190562A (es) | 2017-05-12 | 2020-03-04 | Calithera Biosciences Inc | Método para preparar (3r, 4s)-3-acetamido-4-alil-n-(terc-butil)pirrolidina-3-carboxamida |
| US11655260B2 (en) | 2017-12-22 | 2023-05-23 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as arginase inhibitors |
| CN117180290A (zh) | 2018-02-17 | 2023-12-08 | 阿斯利康(瑞典)有限公司 | 精氨酸酶抑制剂及其使用方法 |
| US12054500B2 (en) | 2018-03-05 | 2024-08-06 | Arcus Biosciences, Inc. | Arginase inhibitors |
| WO2019177873A1 (en) | 2018-03-13 | 2019-09-19 | Merck Sharp & Dohme Corp. | Arginase inhibitors and methods of use |
| US10851099B2 (en) | 2018-03-29 | 2020-12-01 | Oncoarendi Therapeutics S.A. | Dipeptide piperidine derivatives |
| WO2019245890A1 (en) | 2018-06-20 | 2019-12-26 | Merck Sharp & Dohme Corp. | Arginase inhibitors and methods of use |
| CN113382998A (zh) | 2018-11-16 | 2021-09-10 | 艾库斯生物科学有限公司 | Arg1和/或arg2的抑制剂 |
| CN109364252B (zh) * | 2018-11-21 | 2021-09-28 | 南京大学 | 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用 |
| EP3897622A4 (en) | 2018-12-18 | 2022-09-28 | Merck Sharp & Dohme Corp. | Arginase inhibitors and methods of use |
| EP3917936A4 (en) * | 2019-02-06 | 2022-12-14 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | ALKYBORONIC ACIDS AS ARGINASE INHIBITORS |
| CN113727975A (zh) * | 2019-05-02 | 2021-11-30 | 阿克拉瑞斯治疗股份有限公司 | 作为jak抑制剂的被取代的吡咯并吡啶 |
| MX2022000904A (es) * | 2019-07-23 | 2022-05-02 | Astrazeneca Ab | Inhibidores de arginasa y métodos de uso de estos. |
| CN110615753A (zh) * | 2019-09-02 | 2019-12-27 | 南京新酶合医药科技有限公司 | 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法 |
| CN110759843A (zh) * | 2019-09-30 | 2020-02-07 | 东北师范大学 | 一种氟叠氮取代的四元杂环化合物的制备和应用 |
| CN110734456A (zh) * | 2019-11-06 | 2020-01-31 | 南京谷睿生物科技有限公司 | 一种化合物及其制备方法和医药上的应用 |
| WO2021096542A1 (en) | 2019-11-12 | 2021-05-20 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing ido antagonist prodrugs useful in the treatment of cancer and methods thereof |
| US20230140132A1 (en) * | 2020-01-07 | 2023-05-04 | Merck Sharp & Dohme Llc | Arginase inhibitors and methods of use |
| US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| EP4620469A3 (en) | 2020-07-02 | 2025-10-01 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| US20220041630A1 (en) * | 2020-07-17 | 2022-02-10 | Incyte Corporation | Processes for the preparation of arginase inhibitors and their synthetic intermediates |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
| AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
| GEAP202416612A (en) | 2022-03-17 | 2024-12-10 | Incyte Corp | Tricyclic urea compounds as jak2 v617f inhibitors |
| TW202416968A (zh) | 2022-10-21 | 2024-05-01 | 美商英塞特公司 | 作為ｊａｋ２ ｖ６１７ｆ抑制劑之三環脲化合物 |
| US20240317744A1 (en) | 2023-03-13 | 2024-09-26 | Incyte Corporation | Bicyclic Ureas As Kinase Inhibitors |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| DK0999825T3 (da) | 1997-07-29 | 2004-02-09 | Alcon Lab Inc | Oftalmiske sammensætninger indeholdende galactomannanpolymerer og borater |
| CA2305703A1 (en) | 1997-10-10 | 1999-04-22 | David W. Christianson | Compositions and methods for inhibiting arginase activity |
| EP1051167A1 (en) | 1998-01-29 | 2000-11-15 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-) -bupropion |
| US20040063666A1 (en) | 1998-10-09 | 2004-04-01 | David Christianson | Compositions for inhibiting arginase activity |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| AU2001275870A1 (en) | 2000-07-06 | 2002-01-21 | Fal Diagnostics | Methods and kits for the detection of arginine compounds |
| CA2431080A1 (en) | 2003-06-02 | 2004-12-02 | Catherine Adele O'brien | Enhancement of anticancer immunity through inhibition of arginase |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| US8512717B2 (en) | 2003-08-07 | 2013-08-20 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| EP1915143A4 (en) | 2005-07-01 | 2009-11-11 | Univ Johns Hopkins | ARGINASE II: TARGET TREATMENT FOR THE AGING HEART AND HEART FAILURE |
| US20100189544A1 (en) | 2007-07-12 | 2010-07-29 | Sanyo Denki Co., Ltd. | Counter-rotating axial-flow fan |
| JP5421272B2 (ja) * | 2007-10-12 | 2014-02-19 | リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド | 眼病治療のための組成物及び方法 |
| MX2010012064A (es) * | 2008-05-05 | 2010-12-06 | Schering Corp | Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer. |
| PT2389352T (pt) | 2009-01-26 | 2019-08-23 | Astrazeneca Uk Ltd | Inibidores de arginase e métodos de utilização |
| MX348422B (es) | 2010-04-22 | 2017-06-12 | Mars Inc | Inhibidores de arginasa y sus aplicaciones terapeuticas. |
| JP5909239B2 (ja) * | 2010-10-26 | 2016-04-26 | マーズ インコーポレイテッド | アルギナーゼ阻害剤としてのボロネート |
| RU2019121905A (ru) | 2010-12-31 | 2019-09-03 | Астразенека Юкей Лимитед | Ингибиторы аргиназы и способы их применения |
| CN104244932B (zh) | 2011-10-19 | 2017-02-22 | 马尔斯公司 | 精氨酸酶抑制剂和其治疗应用 |
| ES2627347T3 (es) | 2011-10-20 | 2017-07-27 | Glaxosmithkline Llc | Aza-heterociclos bicíclicos sustituidos y análogos como moduladores de sirtuina |
| AU2013249790B2 (en) | 2012-04-18 | 2018-01-25 | Mars, Incorporated | Ring constrained analogs as Arginase inhibitors |
| MX2015005633A (es) * | 2012-11-02 | 2016-02-03 | Pharmacyclics Inc | Terapia adyuvante con inhibidores de quinasa de la familia tec. |
| MX2016005283A (es) * | 2013-10-25 | 2017-02-20 | Pharmacyclics Llc | Tratamiento que utiliza inhibidores de tirosina quinasa de bruton e inmunoterapia. |
| CN105879030A (zh) * | 2014-09-30 | 2016-08-24 | 复旦大学 | 治疗肿瘤的增效药物复合物及其制备方法 |
| WO2016153078A1 (en) * | 2015-03-20 | 2016-09-29 | Opiyo Sammy Oyoo | Use of suramin and arginase inhibitors in malignant neoplasia |
| CN107921051A (zh) | 2015-06-23 | 2018-04-17 | 卡里塞拉生物科学股份公司 | 抑制精氨酸酶活性的组合物和方法 |
| CA3003271A1 (en) | 2015-10-30 | 2017-05-04 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
-
2016
- 2016-10-28 CA CA3003271A patent/CA3003271A1/en active Pending
- 2016-10-28 CR CR20210389A patent/CR20210389A/es unknown
- 2016-10-28 NZ NZ742742A patent/NZ742742A/en not_active IP Right Cessation
- 2016-10-28 EP EP20165627.9A patent/EP3693375B1/en active Active
- 2016-10-28 US US15/337,041 patent/US10065974B2/en active Active
- 2016-10-28 SG SG10201911402YA patent/SG10201911402YA/en unknown
- 2016-10-28 WO PCT/US2016/059342 patent/WO2017075363A1/en not_active Ceased
- 2016-10-28 CN CN202110097870.5A patent/CN113150015A/zh active Pending
- 2016-10-28 PL PL16860883T patent/PL3368541T3/pl unknown
- 2016-10-28 AU AU2016343656A patent/AU2016343656B2/en not_active Ceased
- 2016-10-28 PT PT168608834T patent/PT3368541T/pt unknown
- 2016-10-28 CN CN202110099500.5A patent/CN113201002A/zh active Pending
- 2016-10-28 TW TW105135189A patent/TWI710565B/zh not_active IP Right Cessation
- 2016-10-28 EA EA201891057A patent/EA038276B1/ru unknown
- 2016-10-28 RS RS20200836A patent/RS60695B1/sr unknown
- 2016-10-28 MA MA43131A patent/MA43131B1/fr unknown
- 2016-10-28 MD MDE20180870T patent/MD3368541T2/ro unknown
- 2016-10-28 BR BR122020022280-8A patent/BR122020022280B1/pt active IP Right Grant
- 2016-10-28 EP EP16860883.4A patent/EP3368541B1/en active Active
- 2016-10-28 EP EP22150809.6A patent/EP4011887B1/en active Active
- 2016-10-28 PH PH1/2022/551082A patent/PH12022551082A1/en unknown
- 2016-10-28 BR BR122020022275-1A patent/BR122020022275B1/pt active IP Right Grant
- 2016-10-28 SM SM20200469T patent/SMT202000469T1/it unknown
- 2016-10-28 TW TW110129153A patent/TWI775556B/zh not_active IP Right Cessation
- 2016-10-28 MY MYPI2018701596A patent/MY201783A/en unknown
- 2016-10-28 SG SG10201911406TA patent/SG10201911406TA/en unknown
- 2016-10-28 ES ES22150809T patent/ES2991555T3/es active Active
- 2016-10-28 ES ES16860883T patent/ES2808988T3/es active Active
- 2016-10-28 BR BR112018008746-7A patent/BR112018008746B1/pt not_active IP Right Cessation
- 2016-10-28 DK DK22150809.6T patent/DK4011887T3/da active
- 2016-10-28 CR CR20210390A patent/CR20210390A/es unknown
- 2016-10-28 MX MX2018005294A patent/MX2018005294A/es unknown
- 2016-10-28 CN CN202110099502.4A patent/CN113150016A/zh active Pending
- 2016-10-28 PH PH1/2018/500899A patent/PH12018500899B1/en unknown
- 2016-10-28 UA UAA201805902A patent/UA125289C2/uk unknown
- 2016-10-28 SI SI201630892T patent/SI3368541T1/sl unknown
- 2016-10-28 CN CN201680063897.XA patent/CN108271371B/zh active Active
- 2016-10-28 ES ES20165627T patent/ES2910928T3/es active Active
- 2016-10-28 TW TW109135297A patent/TWI734630B/zh not_active IP Right Cessation
- 2016-10-28 HR HRP20201046TT patent/HRP20201046T1/hr unknown
- 2016-10-28 SG SG10202003966RA patent/SG10202003966RA/en unknown
- 2016-10-28 SG SG11201802961PA patent/SG11201802961PA/en unknown
- 2016-10-28 HU HUE16860883A patent/HUE054972T2/hu unknown
- 2016-10-28 JP JP2018522126A patent/JP6833844B2/ja active Active
- 2016-10-28 CR CR20180282A patent/CR20180282A/es unknown
- 2016-10-28 KR KR1020187015208A patent/KR102434308B1/ko active Active
- 2016-10-28 MA MA050636A patent/MA50636A/fr unknown
- 2016-10-28 KR KR1020227028040A patent/KR20220118559A/ko active Pending
- 2016-10-28 LT LTEP16860883.4T patent/LT3368541T/lt unknown
- 2016-10-28 DK DK16860883.4T patent/DK3368541T3/da active
-
2018
- 2018-04-16 IL IL258731A patent/IL258731B/en active IP Right Grant
- 2018-04-27 CL CL2018001134A patent/CL2018001134A1/es unknown
- 2018-05-02 CO CONC2018/0004750A patent/CO2018004750A2/es unknown
- 2018-05-28 EC ECIEPI201840250A patent/ECSP18040250A/es unknown
- 2018-05-29 ZA ZA2018/03556A patent/ZA201803556B/en unknown
- 2018-08-10 US US16/101,275 patent/US10851118B2/en not_active Expired - Fee Related
-
2019
- 2019-03-28 CL CL2019000820A patent/CL2019000820A1/es unknown
- 2019-03-28 CL CL2019000821A patent/CL2019000821A1/es unknown
- 2019-03-28 CL CL2019000819A patent/CL2019000819A1/es unknown
- 2019-10-28 ZA ZA2019/07092A patent/ZA201907092B/en unknown
- 2019-10-28 ZA ZA2019/07093A patent/ZA201907093B/en unknown
- 2019-10-28 ZA ZA2019/07091A patent/ZA201907091B/en unknown
-
2020
- 2020-03-23 US US16/827,503 patent/US10844080B2/en active Active
- 2020-08-21 CY CY20201100780T patent/CY1123557T1/el unknown
- 2020-11-12 US US17/096,500 patent/US20210061822A1/en not_active Abandoned
- 2020-12-10 AU AU2020286278A patent/AU2020286278B2/en not_active Ceased
-
2021
- 2021-02-02 JP JP2021014795A patent/JP7032583B2/ja not_active Expired - Fee Related
- 2021-03-15 IL IL281503A patent/IL281503B/en unknown
- 2021-11-18 IL IL288225A patent/IL288225A/en unknown
-
2022
- 2022-02-22 JP JP2022025334A patent/JP2022071010A/ja not_active Withdrawn
- 2022-05-31 AU AU2022203703A patent/AU2022203703A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018001134A1 (es) | Composiciones y métodos para inhibir la actividad arginasa | |
| CO2019007839A2 (es) | Composiciones y métodos para inhibir la acción de la arginasa | |
| AR121273A2 (es) | Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende | |
| CR20150316A (es) | Compuestos y sus métodos de empleo | |
| MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
| MX2016013457A (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| MX2017010773A (es) | Inhibidores de muerte programada 1 (pd-19)/ligando de muerte progamada 1 (pd-l1) para el tratamiento de cancer. | |
| CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
| CL2017002786A1 (es) | Referencia cruzada a solicitudes relacionadas | |
| MX2020011104A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| MX2016002137A (es) | Ciertas entidades quimicas, composiciones y metodos. | |
| NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
| CL2016001131A1 (es) | Uso de una combinación farmacéutica que comprende un compuesto inhibidor de mdm2 y uno o más agentes activos adicionales para el tratamiento del cáncer y composiciones farmacéuticas que comprenden dichas combinaciones. | |
| BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
| CL2015002151A1 (es) | Biaril amide compuestos como inhibidores de quinasa | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
| GT201700167A (es) | Terapias de combinación para el tratamiento de cánceres. | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| CL2017002170A1 (es) | Desacetoxitubulisina h y análogos de esta. | |
| DOP2018000066A (es) | Compuestos útiles para inhibir ror-gamma-t | |
| MX2017001352A (es) | Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2). | |
| CL2016001232A1 (es) | Inhibidores tetracíclicos de autotaxina | |
| MX2017011018A (es) | Inhibicion de la actividad de olig2. | |
| MX2017010002A (es) | Terapias de combinacion. |